IVVD Reports $17.2M Q4 Revenue, $226.7M Cash, Initiates DECLARATION Phase 3 Trial, FDA Fast Track for VYD2311, Appoints CMO
Invivyd, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.22
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS